Sclerostin and the inhibition of wnt signaling and bone formation
AssigneeEnzo Biochem, Inc.
InventorsDAN DIANQING WU, XIAOFENG LI
Life of this patent
Estimating the term…
Loading patent…
AssigneeEnzo Biochem, Inc.
InventorsDAN DIANQING WU, XIAOFENG LI
Estimating the term…
The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.
1-97. (canceled)
A method for identifying a drug candidate or compound which promotes or inhibits a protein-protein interaction comprising:
A method for identifying a drug candidate or compound which promotes or inhibits a protein-protein interaction comprising:
A method for identifying a drug candidate compound which binds to a receptor protein involved in bone formation or bone remodeling comprising:
A method for identifying a drug candidate compound which binds to a receptor protein involved in bone formation or bone remodeling comprising:
A method for identifying a drug candidate or compound which binds to a protein involved in a signal transduction system comprising:
A method for identifying a drug candidate or compound which binds to a nonsoluble or membrane-bound protein involved in a signal transduction system comprising:
A method for identifying a drug candidate or compound which binds to a protein involved in a Wnt signaling pathway comprising:
A method for identifying a drug candidate or compound which binds to a protein involved in a signal transduction system for promoting or inhibiting bone growth comprising:
A method for the regulation of bone formation or bone remodeling comprising administering at least one non-native compound, at least one fragment of a non-native compound, or any combination thereof, that decreases or eliminates the affinity of sclerostin to a receptor or co-receptor involved in bone formation or bone remodeling.
Dependencies are inferred from the claim text.